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Abstract
I In nt tr ro od du uc ct ti io on n: :   Implantation of an aortic-bifemoral prosthesis is characterised by
a high (> 5%) rate of perioperative cardiovascular events. The main aim of the
study is to demonstrate the usefulness of the determination of NT-proBNP
concentration as a method of risk stratification of left ventricular dysfunction
in patients subjected to surgery for aortic-bifemoral prosthesis implantation. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   Forty consecutive patients were examined and subjected
to aortic-bifemoral prosthesis implantation. The examined patients were divided
into two groups: 1) with normal left ventricular systolic function and EF ≥ 58%
(group I), 2) with left ventricular systolic dysfunction and EF < 58% (group II).
R Re es su ul lt ts s: :    In  group  I the  median  EF  before  surgery  was  69.5%  and  the
concentration of NT-proBNP 141.5 pg/ml. On day 7 after surgery respective values
were EF 65.5%, NT-proBNP 498.55 pg/ml. In group II the median EF before
surgery was 54%, and NT-proBNP concentration 303.9 pg/ml.
C Co on nc cl lu us si io on ns s: :   The concentration of plasma NT-proBNP before surgery well
correlated with left ventricular ejection fraction. The values of NT-proBNP > 303.9
pg/ml  strongly  correlated  with  increased  risk  of  left  ventricular  systolic
dysfunction after surgery and they seem to have high prognostic value for the
occurrence of cardiovascular events in this group of patients. The determination
of NT-proBNP level on day 7 after surgery strongly correlated with the decrease
of left ventricular ejection fraction in patients after the prosthesis implantation.
It is a valuable diagnostic and prognostic factor of circulatory system efficiency
before making a decision to discontinue hospitalization. 
K Ke ey y   w wo or rd ds s: :   NT-proBNP, abdominal aortic aneurysm, Leriche syndrome, clamping
syndrome, heart failure.
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Introduction
Major  non-cardiac  surgical  procedures  are
associated with significant postoperative morbidity
and mortality. The majority of deaths in this setting
correlate  with  cardiac  complications  such  as
myocardial  infarction.  Major  surgery  is  also
associated with increased prevalence of stroke,
non-fatal myocardial ischaemia and malignant
arrhythmia.  So  far,  a few  systems  have  been
described for the estimation of perioperative risk in
this group of patients. 
Implantation of an aortic-bifemoral prosthesis is
characterised by a high (> 5%) rate of perioperative
cardiovascular events. The risk stratification of
complications in non-cardiac surgical procedures is
difficult in this population of patients; it is difficult
to estimate cardiovascular system efficiency due to
the basic disease preventing patients from making
even a slight effort. In patients with asymptomatic
and symptomatic heart failure N-terminal pro-B-type
natriuretic peptide (NT-proBNP) concen  tration is
a strong predictor of cardiovascular events or death
[1, 2].
The main aim of the study is to demonstrate the
usefulness  of  the  determination  of  plasma 
NT-proBNP concen  tration as a method of risk strati  -
fication of left ventricular dysfunction in patients
with Leriche’s syndrome and abdominal aortic
aneurysm subjected to surgery for aortic-bifemoral
prosthesis implantation. 
Material and methods
S St tu ud dy y   g gr ro ou up p
Forty consecutive patients were examined and
subjected to aortic-bifemoral prosthesis implan  -
tation in the Vascular Surgery Unit of M. Pirogow
Provincial Specialist Hospital in Lodz within the
period from September 2007 to April 2008. All the
study participants had signed the consent form
before they were included in the study, which was
approved by the local Ethics Committee of the
Medical University of Lodz.
The examined patients were divided into two
groups: 1) with normal left ventricular systolic
function and ejection fraction (EF) ≥ 58% (group I),
2) with left ventri  cular systolic dysfunction and EF
< 58% (group II).
Each group included 20 examined patients in the
same age range. The patients from both groups
were  selected  for  the  examination  after  prior
qualification  for  surgery  by  vascular  surgery
specialists from M. Pirogow Hospital in Lodz. All the
patients  qualified  for  surgical  procedure  were
subjected to the following examinations:
– ultrasonographic (USG) of abdominal aorta and
lower limb vessels, 
– abdominal computed tomography (CT) or abdo  -
minal aorta angiography,
– thoracic X-ray,
– arterial  blood  pressure  measurement  by
Korotkov’s method and pulse evaluation,
– electrocardiogram (ECG),
– echocardiography  with  EF  evaluation  using
modified Simpson’s technique according to the
guidelines of the American Society of Echocardio  -
graphy before surgery and on day 7 after the
procedure,
– laboratory blood tests: blood cell count, electro  -
lytes, glucose, urea, creatinine, total cho  lesterol,
LDL, HDL, triglycerides,
– determination of NT-proBNP level before surgery
and on day 7 after the procedure using the
immunochemical electroluminescence method
worked out by Roche Diagnostics, on an Elecsys
2010 analyser. 
C Ch ha ar ra ac ct te er ri is st ti ic cs s   o of f   t th he e   e ex xa am mi in ne ed d   g gr ro ou up p
Clinical assessment of the risk of cardiac events
was carried out in accordance with the cardiac risk
index according to Lee et al. [3]. A preoperative
cardiac risk score was calculated by assigning 
1 point to each of the following cardiac risk factors:
high-risk type of surgery (> 5%), ischaemic heart
disease or previous myocardial infarction, history
of heart failure, history of cerebrovascular disease
or previous stroke, insulin therapy for diabetes
mellitus, renal dysfunction (defined as preoperative
serum creatinine level > 2.0 mg/dl [177 ﾵmol/l]). 
Detailed characteristics of the examined groups
are presented in Table I. Implantation of an aortic-
bifemoral prosthesis was performed in 24 patients
with abdominal aortic aneurysm and in 16 patients
with Leriche’s syndrome. 
All surgical procedures were performed under
general anaesthesia. In the perioperative period
standard medical care was supplied. The duration
of  the  surgery  was  registered  as  well  as  of
abdominal aortic clamping and blood loss in the
course of the surgery (Table II).
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Nonparametric  statistics  was  used  for  the
comparison of two variables based on the Wilcoxon
rank sum test. The procedure assumes that the
considered variables were measured on a scale
enabling  one  to  rank  observations  within  each
variable (ordinal scale) and to rank the differences
between variables. The EF, NT-proBNP, HR, haemo  -
globin and haematocrit values were compared before
surgery and on day 7 after the procedure. The dura  -
tion of the surgery and aortic clamping as well as
blood loss during the procedure were also analysed. 
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Results
The study population consisted of 20 patients
with normal left ventricular systolic function and
EF  ≥ 58%  (group  I)  and  20  patients  with  left
ventricular systolic dysfunction (group II). The mean
age in group I was 58.1 ﾱ17.7 years (70% men), in
group II 55.3 ﾱ25.6 years (85% men). In the group
with normal systolic function 5 patients (25%) had
confirmed ischaemic heart disease (IHD), and 1 of
them had a history of myocardial infarction. In
group II, 12 patients had IHD (60%), 7 myocardial
infarction (35%), and 1 previous surgical myocardial
revascularisation. 
The  number  of  examined  patients  in  both
groups according to cardiac risk index according to
Lee [3] is presented in Table III.
In group I the median left ventricular EF before
surgery was 69.5% (1st and 3rd quartile respectively
67%  and  73.3%),  and  the  concentration  of 
NT-proBNP  141.5  pg/ml  (1st and  3rd  quartile
respectively 101.64 pg/ml and 210.78 pg/ml). On
day 7 after surgery respective values were EF 65.5%
(1st and  3rd quartile  respectively  63.75%  and
73.32%), NT-proBNP 498.55 pg/ml (1st and 3rd
quartile respectively 232.33 pg/ml and 744.5 pg/
ml). No statistical significance was observed for
the decrease of ejection fraction (p = 0.432622).
However, a statistically significant increase of the
value of serum NT-proBNP concentration was
detected on day 7 after implantation of the aortic-
bifemoral prosthesis (p = 0.000219).
In group II the median left ventricular ejection
fraction (EF) before surgery was 54% (1st and 3rd
quartile respectively 52.75% and 55.78%), and 
NT-proBNP concentration 303.9 pg/ml (1st and 3rd
quartile  respectively  213.95  pg/ml  and  543.13
pg/ml).  On  day  7  after  surgery  a statistically
significant decrease of left ventricular ejection
fraction was observed to 50.5% (1st and 3rd quartile
respectively 49% and 52.25%), whereas the median
NT-proBNP increased statistically significantly to
1522.8 pg/ml (1st and 3rd quartile respectively
834.98 pg/ml and 3431 pg/ml). The examined
groups did not differ statistically significantly as
regards the duration of the surgery, the duration
of  aortic  clamping  or  blood  loss  during  the
procedure.  
Comparing both groups on day 7 after surgery,
a significant increase of NT-proBNP concentration
was observed (median 1522.8 pg/ml) in group I of
patients  with  initially  decreased  EF  <  58%  in
relation to the examined patients in group II with
initially increased EF > 58% (median 498.55 pg/ml),
and  a significant  decrease  of  left  ventricular
ejection fraction in group II patients with initially
decreased EF < 58% (Figures 1 and 2).
In group I on day 7 after implantation of the
aortic-bifemoral prosthesis the increased plasma
NT-proBNP level was accompanied by a statistically
insignificant increase of mean heart rate (HR) 
by 2.3% (p = 0.433054). In group II on day 7 HR
incre  ased  statistically  significantly  by  13.6% 
(p = 0.000780).
A comparable decrease of HCT and HGB value
was  observed  in  both  groups  on  day  7  after
implantation of the aortic-bifemoral prosthesis in
relation to the initial values (Table IV). 
C Ch ha ar ra ac ct te er ri is st ti ic cs s       G Gr ro ou up p   I I G Gr ro ou up p   I II I V Va al lu ue e   o of f   p p
o of f   t th he e   e ex xa am mi in ne ed d    E EF F   > >   5 58 8% % E EF F   < <   5 58 8% %
g gr ro ou up ps s n n = =   2 20 0 n n = =   2 20 0
Age [years] 58.1 ﾱ17.7 55.3 ﾱ25.6 NS
Men [%] 70 85 NS
BMI [kg/m2] 25.1 ﾱ4.4 24.9 ﾱ4 NS
BSA 1.9 ﾱ0.2 1.9 ﾱ0.2 NS
IHD [%] 25 60 < 0.05
Previous myocardial  5 35 < 0.05
infarction [%]
Heart failure [%] 20 40 NS
Previous CNS  00 NS
ischaemia [%]
Previous CABG [%] 05 NS
Renal failure [%] 10 5 NS
Hypertension [%] 75 70 NS
Diabetes [%] 0 20 < 0.05
Hypercholestero- 45 50 NS
laemia [%]
Cigarette smoking [%] 65 60 NS
Abnormal ECG [%] 25 60 < 0.05
Pathological Q  5 25 < 0.05
waves [%]
Wall motion abnor- 5 45 < 0.05
malities at rest [%]
LV hypertrophy [%] 40 40 NS
Abdominal aortic  65 55 NS
aneurysm [%]
Leriche’s syndrome [%] 35 45 NS
ASA [%] 20 75 < 0.05
ACEI [%] 60 60 NS
Sartans [%] 10 5 NS
ʲ-Blockers [%] 40 45 NS
Calcium antagonists [%] 15 10 NS
Digoxin [%] 00 NS
Diuretics [%] 20 30 NS
Nitrates [%] 0 25 < 0.05
Statins [%] 30 55 < 0.05
T Ta ab bl le e   I I. .   Characteristics of the examined groups
n – number of patients, p – difference significant, NS – difference
statistically insignificant
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Discussion
The level of NT-proBNP is useful information in
patients with suspected heart failure and a valuable
prognostic marker in patients with heart failure,
acute coronary syndromes, valvular heart disease
or other circulatory system pathologies. Increasing
numbers of studies confirm that elevated BNP and
NT-proBNP levels predict many causes of mortality
and cardiovascular events including heart failure,
myocardial infarction, shock, atrial fibrillation and
sudden death in stable patients with known or
unknown circulatory system disease, and they
provide  information  about  cardiovascular  risk
regardless of the risk factors used so far [4, 5]. Also
in low risk patients with stable ischaemic heart
disease and preserved ventricular function, BNP
and NT-proBNP are highly sensitive and specific
prognostic markers in comparison to standard risk
factors [6]. High sensitivity and diagnostic specificity
of NT-proBNP was demonstrated in oligo  sympto  -
matic left ventricular dysfunction defined as left
ventricular ejection fraction < 58% [6, 7]. One of the
most significant diagnostic applications of natriu  -
G Gr ro ou up p   I I HGB – day 0  13.8 ﾱ1.8 p = 0.001697
E EF F   > >   5 58 8% % HGB – day 7  11.9 ﾱ1.5
n n = =   2 20 0
HCT – day 0  40.3 ﾱ4.9 p = 0.001475
HCT – day 7  34.4 ﾱ4.2
G Gr ro ou up p   I II I HGB – day 0  13.7 ﾱ1.6 p = 0.002979
E EF F   < <   5 58 8% % HGB – day 7  11.8 ﾱ1.8
n n = =   2 20 0
HCT – day 0  39.9 ﾱ4.2 p = 0.009637
HCT – day 7  33.7 ﾱ5.2
T Ta ab bl le e   I IV V. . Comparison of HGB and HCT values in
Group I and II before (0) and on day 7 after surgery
G Gr ro ou up p   I I G Gr ro ou up p   I I G Gr ro ou up p   I II I    G Gr ro ou up p   I II I   
– –   0 0   d da ay y – –   7 7   d da ay y – –   0 0   d da ay y    – –   7 7   d da ay y
F Fi ig gu ur re e   1 1. .   Comparison of the value of left ventricular
ejection fraction in groups I and II before surgery 
(day 0) and on day 7 after implantation of aortic-
bifemoral prosthesis 
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C Ca ar rd di ia ac c   r ri is sk k   i in nd de ex x    G Gr ro ou up p   I I G Gr ro ou up p   I II I V Va al lu ue e   o of f   p p
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P Pa ar ra am me et te er rs s G Gr ro ou up p   I I G Gr ro ou up p   I II I V Va al lu ue e   o of f   p p
E EF F   > >   5 58 8% % E EF F   < <   5 58 8% %
n n = =   2 20 0 n n = =   2 20 0
Duration of surgery  132.3 ﾱ31.9 135.0 ﾱ32.4 NS
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statistically insignificant
85
80
75
70
65
60
55
50
45
40
Prognostic value of plasma N-terminal pro-B-type natriuretic peptide concentration in patients with normal and impaired left ventricular
systolic function undergoing surgery for abdominal aortic aneurysm646 Arch Med Sci 4, August / 2011
retic peptides determination is their high negative
predictive value, reaching 99%, excluding heart
failure [8].
In the group of patients subjected to aortic-
bifemoral prosthesis implantation it is very impor  -
tant to establish the risk of cardiovascular events,
particularly in older patients who probably have
circulatory system disease and whose reaction to
transfusion and fluid therapy may decompensate
their  circulatory  system.  Furthermore,  their
cardiovascular system is exposed to the increase
of afterload during aortic clamping as well as to
early or late post-perfusion syndrome. There are
only  single  reports  concerning  studies  on  the
relation of the level of plasma natriuretic peptides
as a prognostic factor of morbidity and mortality of
patients subjected to major non-cardiac surgery,
particularly  to  the  implantation  of  an  aortic-
bifemoral prosthesis. 
Feringa et al. evaluated 170 patients: 67 (39%)
were subjected to abdominal aortic repair, and 103
(61%) to lower extremity revascularization. During
a follow-up of 30 days the patients were observed
as regards cardiac events. The aim of the study was
to assess the value of NT-proBNP for predicting
postoperative cardiac events in patients undergoing
major non-cardiac surgery, in addition to clinical data
and dobutamine stress echocardiographic results.
The median NT-proBNP level was higher in the group
of  patients  with  postoperative  cardiac  events 
(939 pg/ml, interquartile range from 634 to 2469)
compared with patients with no cardiac events 
(101 pg/ml, interquartile range from 40 to 304) 
(p < 0.0001). The level of NT-proBNP ≥ 533 pg/ml was
identified as the optimal predictor of postoperative
cardiac events in these patients [9]. In a consecutive
prospective study in 182 vascular surgery patients,
the association was evaluated between NT-proBNP
concentration, myocardial ischaemia, troponin T level
and HRV. Elevated level of NT-proBNP ≥ 270 ng/l was
associated  with  higher  perioperative  risk  of
myocardial ischaemia and troponin T release. No
correlation was found between preoperative HRV and
NT-proBNP levels [10].
In a study on two groups – 41 patients with very
high risk of cardiovascular events subjected to high
risk surgical procedures (amputation, aortic surgery,
peripheral bypass) who participated in the North
Glasgow MONICA study and 149 patients from
a low cardiac risk group undergoing major non-
cardiosurgical procedures (vascular procedures,
laparotomies, thoracotomies) – the usefulness of
preoperative determination of the BNP level for
predicting  postoperative  cardiac  events  was
analysed. Preoperative level of BNP > 108.5 pg/ml
was  demonstrated  to  predict  in  both  groups
postoperative cardiac events in patients subjected
to  major  non-cardiac  procedures  with  87%
sensitivity and specificity regardless of other risk
factors 11].
In another study investigating the usefulness of
the determination of BNP level in risk stratification
of cardiac events in patients subjected to major
non-cardiac surgery, it was demonstrated that the
level of BNP > 40 pg/ml with 75% sensitivity and
70% specificity was associated with higher risk of
perioperative myocardial infarction and death. The
patients who in the postoperative period had ECG
abnormalities  and  elevated  troponin  I level
demonstrated higher preoperative plasma BNP
levels [12].
Yeh  et  al.  demonstrated  that  the  level  of 
NT-proBNP > 450 pg/ml predicted postoperative
cardiac events in 190 patients undergoing non-
cardiac surgery. Fifteen of 190 patients had cardiac
complications: 4 – acute coronary syndrome, 13 –
heart failure. The NT-pro-BNP level was significantly
higher in patients with cardiac complications;
a level > 450 ng/ml was predictive of cardiac
complications  with  a sensitivity  of  100%  and
specificity of 82.9% [13].
However,  in  another  study  based  on  1590
patients it was demonstrated that preoperative
level of BNP > 189 pg/ml was the only independent
factor  identifying  patients  at  highest  risk  of
postoperative cardiovascular events in comparison
to Goldman’s multifactorial index of cardiac risk [14]
and to left ventricular ejection fraction [15]. Cardiac
events  occurred  in  6%  of  patients:  21  cardiac
deaths, 20 non-fatal myocardial infarctions, 41
episodes of pulmonary oedema and 14 patients
with ventricular tachycardia. All these patients had
a preoperative level of BNP > 189 pg/ml. It should
be mentioned that in this study 15 patients with
serious postoperative cardiac events had a level of
BNP < 189 pg/ml and 233 patients without any
postoperative cardiac events had an elevated BNP
level greater than 189 pg/ml. In this study there
were no patients with postoperative cardiac events
and an initial level of BNP < 100 pg/ml, and no
patients with a history of cardiac events and an
initial level of BNP < 100 pg/ml which does not
exclude  a history  of  myocardial  infarction  or
asymptomatic left ventricular dysfunction. 
In this study values of NT-proBNP > 303.9 pg/ml
strongly  correlated  with  increased  risk  of  left
ventricular systolic dysfunction after implantation
of the aortic-bifemoral prosthesis and they seem
to have high prognostic value for the occurrence of
postoperative cardiovascular events in this group
of patients. They distinguish a group of patients
requiring  special  preoperative  pharmaceutical
preparation, particularly normalization of water-
electrolyte balance and preoperative ʲ-blockade
[16]. The statement seems to be right that the
determination  of  plasma  natriuretic  level  in
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perioperative risk stratification of aortic-bifemoral
prosthesis implantation is a marker of cardio  -
vascular events independent of left ventricular
echocardiography and it is valuable information
about perioperative circulatory system efficiency at
low cost of the diagnostic test [17]. 
In  conclusion,  the  concentration  of  plasma 
NT-proBNP  before  aortic-bifemoral  prosthesis
implantation correlated well with left ventricular
ejection fraction. The values of NT-proBNP > 303.9
pg/ml strongly correlated with increased risk of left
ventricular  systolic  dysfunction  after  aortic-
bifemoral prosthesis implantation and they seem
to have high prognostic value for the occurrence of
cardiovascular events in this group of patients. The
determination of NT-proBNP level on day 7 after
aortic-bifemoral prosthesis implantation strongly
correlated with the decrease of left ventricular
ejection  fraction  in  patients  after  prosthesis
implantation.  It  is  a valuable  diagnostic  and
prognostic factor of circulatory system efficiency
before making a decision to discontinue hospi  -
talization. 
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